Yugo Chisaki
6PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|May 03, 2025
Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective.Yugo Chisaki, Nobuhiko Nakamura, Takako Komuro
|May 09, 2024
Analysis of Barriers to Medical Opioid Pain Medication Using the Japanese Version of the Barriers Questionnaire II (JBQ-II): Pharmacists and Nurses Perspective in Japan.Yugo Chisaki, Mika Oomoto, Yuika Sakurano
|Oct 27, 2023
Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.Yugo Chisaki, Hajime Nakano, Juna Minamide
|Oct 18, 2022
A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors.Hiroki Hata, Chikako Matsumura, Yugo Chisaki
|Jan 10, 2022
The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study.Yugo Chisaki, Hiroki Hata, Chikako Matsumura
|Mar 06, 2021
Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.Yugo Chisaki, Yoshiki Kuwada, Chikako Matsumura
Pageof 1
